Rosetta Genomics has been in business for more than 9 years. The company is committed to improving human health through the use of microRNA applications. The tests and treatments developed by Rosetta Genomics are designed to meet a wide range of global healthcare needs.
The mission of Rosetta Genomics is to:

• Lead the development of new and accurate cancer diagnostics based on microRNA technology
• Address unmet medical needs that will advance personalized medicine
• Enhance current and future patient care management

Rosetta Genomics is committed to meeting the highest standards in terms of ethics, responsibility, and accountability. Rosetta Genomics empowers its employees at every level and encourages them to strive for excellence.

Last September, Rosetta Genomics won the Medical-Biotech category of the Wall Street Journal’s Technology Innovation Awards for the development of its microRNA-based diagnostic tests.
The miRview™ meso assay uses quantitative real-time PCR (qRT-PCR) technology to determine the expression of microRNA in tumor tissue. miRview™ meso clearly differentiates malignant pleural mesothelioma from peripheral adenocarcinomas of the lung or metastatic carcinomas involving the lung pleura.